CN102186505A - 成像和放射治疗方法 - Google Patents

成像和放射治疗方法 Download PDF

Info

Publication number
CN102186505A
CN102186505A CN2009801423890A CN200980142389A CN102186505A CN 102186505 A CN102186505 A CN 102186505A CN 2009801423890 A CN2009801423890 A CN 2009801423890A CN 200980142389 A CN200980142389 A CN 200980142389A CN 102186505 A CN102186505 A CN 102186505A
Authority
CN
China
Prior art keywords
alkyl
formula
chemical compound
fluorine
iodine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801423890A
Other languages
English (en)
Chinese (zh)
Inventor
A·卡斯伯特森
P·B·艾弗森
R·巴拉
V·R·库尼伊尔库兰加拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
General Electric Co
Original Assignee
GE Healthcare Ltd
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd, General Electric Co filed Critical GE Healthcare Ltd
Publication of CN102186505A publication Critical patent/CN102186505A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
CN2009801423890A 2008-10-21 2009-10-20 成像和放射治疗方法 Pending CN102186505A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10700108P 2008-10-21 2008-10-21
GB0819280.9 2008-10-21
GBGB0819280.9A GB0819280D0 (en) 2008-10-21 2008-10-21 Imgaing and radiotherapy methods
US61/107001 2008-10-21
PCT/US2009/061271 WO2010048144A2 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods

Publications (1)

Publication Number Publication Date
CN102186505A true CN102186505A (zh) 2011-09-14

Family

ID=40097766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801423890A Pending CN102186505A (zh) 2008-10-21 2009-10-20 成像和放射治疗方法

Country Status (12)

Country Link
US (1) US20110286922A1 (enExample)
EP (1) EP2349351A2 (enExample)
JP (1) JP2012506439A (enExample)
KR (1) KR20110074988A (enExample)
CN (1) CN102186505A (enExample)
AU (1) AU2009307783A1 (enExample)
BR (1) BRPI0919690A2 (enExample)
CA (1) CA2738955A1 (enExample)
GB (1) GB0819280D0 (enExample)
MX (1) MX2011004161A (enExample)
RU (1) RU2011113996A (enExample)
WO (1) WO2010048144A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725003A (zh) * 2009-12-22 2012-10-10 通用电气健康护理有限公司 用于癌症干细胞中的人体肝脏醛脱氢酶进行体内成像的醛类化合物
CN109073556A (zh) * 2016-04-28 2018-12-21 国立大学法人名古屋大学 荧光探针、荧光检测方法及荧光探针的使用方法
CN109715822A (zh) * 2016-07-28 2019-05-03 高级生物设计公司 Aldh同工酶的特异性底物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
AU2005219412A1 (en) 2004-03-02 2005-09-15 Cellectar, Inc. Phospholipid analogs for diagnosis and treatment of cancer
CU23844B1 (es) * 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
JP6092624B2 (ja) * 2009-06-12 2017-03-08 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2013012754A1 (en) * 2011-07-15 2013-01-24 University Of Southern California Boron-based dual imaging probes, compositions and methods for rapid aqueous f-18 labeling, and imaging methods using same
WO2013048832A1 (en) * 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
US8927732B2 (en) * 2012-03-30 2015-01-06 General Electric Company Biotin stannane for HPLC-free radioiodination
US20160008493A1 (en) * 2013-03-15 2016-01-14 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
KR101941223B1 (ko) * 2017-04-04 2019-01-22 을지대학교 산학협력단 복강경 수술용 삼중 융합영상장치
JP2023025307A (ja) * 2020-01-31 2023-02-22 国立大学法人 東京大学 アルデヒドロゲナーゼ１ａ１検出用青色蛍光プローブ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036344A1 (en) * 1995-05-15 1996-11-21 The Johns Hopkins University School Of Medicine Intracellular marker for purification of stem cells
WO2003093498A1 (en) * 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0502277D0 (en) * 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
EP1996182A4 (en) * 2006-02-27 2009-08-12 Univ Johns Hopkins CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS
WO2008036419A2 (en) * 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036344A1 (en) * 1995-05-15 1996-11-21 The Johns Hopkins University School Of Medicine Intracellular marker for purification of stem cells
WO2003093498A1 (en) * 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHE GINESTIER等: "ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome", 《CELL STEM CELL》 *
JACEK WIERZCHOWSKI等: "Fluorimetric Detection of Aldehyde Dehydrogenase Act in Human Blood, Saliva, and Organ Biopsies and Kinetic Differentiation between Class I and Class III Isozymes", 《ANALYTICAL BIOCHEMISTRY》 *
P. MADING,ET AL.: "18F-labelling of a potent nonpeptide CCR1 antagonist:synthesis of 1-(5-chloro-2-{2-[(2R)-4-(4-[18F]fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea in an automated module", 《JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725003A (zh) * 2009-12-22 2012-10-10 通用电气健康护理有限公司 用于癌症干细胞中的人体肝脏醛脱氢酶进行体内成像的醛类化合物
CN109073556A (zh) * 2016-04-28 2018-12-21 国立大学法人名古屋大学 荧光探针、荧光检测方法及荧光探针的使用方法
CN109715822A (zh) * 2016-07-28 2019-05-03 高级生物设计公司 Aldh同工酶的特异性底物

Also Published As

Publication number Publication date
AU2009307783A1 (en) 2010-04-29
GB0819280D0 (en) 2008-11-26
KR20110074988A (ko) 2011-07-05
WO2010048144A3 (en) 2010-07-22
MX2011004161A (es) 2011-06-06
JP2012506439A (ja) 2012-03-15
RU2011113996A (ru) 2012-11-27
BRPI0919690A2 (pt) 2015-12-08
US20110286922A1 (en) 2011-11-24
EP2349351A2 (en) 2011-08-03
CA2738955A1 (en) 2010-04-29
WO2010048144A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
CN102186505A (zh) 成像和放射治疗方法
US20120244074A1 (en) Labelled integrin binders
JP5709841B2 (ja) 標識分子イメージング剤、製造方法及び使用方法
Liu et al. Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment
EP2305316A2 (en) Diphosphorylated glycopeptide imaging agent for fibrosis
CN103242255A (zh) 伊文氏蓝配合物及其制备方法和应用
US11844846B2 (en) Styrylbenzothiazole derivatives and uses in imaging methods
JP2009538894A (ja) インビボイメージング化合物としての四環式オキサゼピン類
JP2009518373A (ja) 線維症用の新規造影剤
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
WO2013048832A1 (en) 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
US20100247435A1 (en) Measurement of neural activity
WO2008003954A1 (en) Dye imaging agents
WO2013048811A1 (en) Imaging and radiotherapy methods for tumour stem cells
US20130101509A1 (en) Imaging and radiotherapy methods
Huang et al. One‐step 18F‐labeling of estradiol derivative for PET imaging of breast cancer
US20080279771A1 (en) Novel Imaging Agents for Cancer
Pham Novel Dual PET And Fluorescent Bioconjugation Reagents for Biomedical Imaging
JP2012042215A (ja) 早期膵がんの検出方法
CN105770921A (zh) 一种针对肿瘤乏氧的pet示踪剂及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110914